<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400620</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-HNC-201-IL</org_study_id>
    <nct_id>NCT01400620</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer</brief_title>
  <official_title>Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izun Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Izun Pharma Ltd</source>
  <oversight_info>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an oral rinse composed of botanical
      extracts is effective in the prevention of severe inflammation of the lining of the oral
      cavity caused by chemotherapy and radiation therapy for head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Proportion of WHO score 3-4 Oral Mucositis at a Cumulative Radiation Dosage of 50 Gy in the active and Placebo Groups</measure>
    <time_frame>Participants will be assessed twice per week during the duration of chemoradiation therapy anticipated to be 5-7 weeks. Following chemoradiation therapy the participants will be assessed weekly for two weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Degree of oral mucositis will be scored using WHO scoring system bi-weekly throughout course of the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 2-3-4 Oral Mucositis as measured by the WHO scale at increasing increments of cumulative radiation exposure</measure>
    <time_frame>Participants will be assessed twice per week during the duration of chemoradiation therapy anticipated to be 5-7 weeks. Following chemoradiation therapy the participants will be assessed weekly for two weeks.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Active oral rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral rinse containing botanical extracts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo rinse</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IZN-6N4</intervention_name>
    <description>Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks</description>
    <arm_group_label>Active oral rinse</arm_group_label>
    <arm_group_label>Placebo rinse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of head and neck cancer

          -  planned treatment course to include Cisplatin and radiation therapy, cumulative
             prescription dose between 50-70 Gy

          -  able to eat at least soft solids

          -  normal cardiac function

          -  able to perform oral rinse

        Exclusion Criteria:

          -  Induction chemotherapy regimen

          -  life threatening allergic reaction to food and/or drugs

          -  history of any other primary malignancy diagnosed within the past 5 years

          -  prior radiation to the sites to be treated

          -  active infections of the oral cavity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel Nussbaum, MD, PhD</last_name>
    <phone>+972 -72-245-8950</phone>
    <phone_ext>101</phone_ext>
    <email>gn@izunpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UF Health Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Beaulieu, MS, CCRC</last_name>
      <phone>352-265-0680</phone>
      <phone_ext>87829</phone_ext>
      <email>SCHMIR@shands.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Amdur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami-Sylvester CCC Clinical Research Services</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilly Sanchez</last_name>
      <phone>305-243-0974</phone>
      <email>Lsanchez@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Samuels, MD, FACR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel - Phillips Ambulatory Care Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rotsen Rocha</last_name>
      <phone>212-844-6286</phone>
      <email>rrocha@CHPNET.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Maria Machuca</last_name>
      <phone>+1-212-844-6286</phone>
      <email>MMachuca@chpnet.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence B Tena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sadaf Eslami</last_name>
      <phone>212-731-6353</phone>
      <email>Sadaf.Eslami@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Katzke, CCRP</last_name>
      <phone>414-805-0599</phone>
      <email>vkatzke@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataly Israeli</last_name>
      <phone>+972-8-624-4127</phone>
      <email>Natalyis@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Olga Belochitski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Froumin</last_name>
      <phone>+972 (4) 7771618</phone>
      <email>g_froumin@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Rahamim Ben Yoseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adi Elfasi</last_name>
      <phone>+972 3-9377973</phone>
      <email>adiel22@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Aharon Popovtzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Burg Golani</last_name>
      <phone>+972 3 6951824</phone>
      <email>tamarbu@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Orit Gutfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigalit Lichtenstein, RN</last_name>
      <phone>+972-3-7645282</phone>
      <email>sigalitl@assuta.co.il</email>
    </contact>
    <investigator>
      <last_name>Raphael Pfeffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rinat Agmon Klein</last_name>
      <phone>+ 972-3-5307033</phone>
      <email>Rinat.AgmonKlein@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Iris Gluck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 9, 2015</lastchanged_date>
  <firstreceived_date>July 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral mucositis</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>head and neck cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
